-
Prediction of intramammary infection status across the dry period from lifetime cow records
Henderson, A. C.; Hudson, C. D., Bradley, A. J.; Sherwin, V. E.; Green, M. J. - Journal of Dairy Science, 2016, Vol. 99: 1-10.
The dry period is very important for mammary gland health, with the aim not only to cure existing intramammary infections (IMI) but also to prevent new IMI. Although it is known hat the dry period is an important time for optimizing udder health, the probability that individual cows will succumb to a new IMI or, if infected, will fail to cure an IMI is not well stablished. The aim of this study was to investigate whether lifetime cow data, available through routine on-farm milk recording, could be used to predict changes in IMI status across the dry period.
-
Prevalence of Bovine Mastitis Pathogens in Bulk Tank Milk in China
Bi, Y.; Wang, YJ.; Qin, Y.; Guix Vallverdú, R.; Maldonado García, J.; Sun, W., et al. (2016)
The objectives of this study were to estimate the herd prevalence ofmajor mastitis pathogens in bulk tank milk (BTM) in China dairy herds, to etermine the relationship between the presence of mastitis pathogens and bulk tank milk somatic cell counts (BTSCC), and to investigate the impact of different dairy cattle farming modes and region on bacterial species. BTM samples collected from 894 dairy herds in China were examined for the presence of mastitis pathogens.
-
An investigation of the efficacy of polyvalent mastitis vaccine using different vaccination regimens under field conditions in the United Kingdom.
Bradley, A.; Journal of Dairy Sci., Jan 2015.
Analysis of milk production data after the use of a commercially available vaccine against mastitis, demonstrated a return on investment of 2.6 to 1 based on milk yield alone.
-
New insights into the immunology of the Bovine Mammary Gland
Schukken, Y.; NMC, 2014.
This article discusses immune response, with a distinction between after intramammary infections in lactaction and after intramammary infection in late gestation.
-
History and benefits of Escherichia coli J5 Mastitis vaccines
Hogan, J.; NMC, 2014
Details of a series of experiments to verify the efficacy of E. coli J5 for controlling Gram-negative bacterial mastitis.
-
Case study of a novel approach to mastitis vaccination in two dairy herds in the United Kingdom.
Drysdale, R.; NMC, 2014.
A simplified vaccination protocol proved effective in reducing severity and case rate of coliform mastitis.
-
STARTVAC® Vaccination against mastitis: estimation of efficacy in dairy herds and immunological response.
Piepers, S.; Buistrissima 2013.
Lower incidence of S.aureus and reduction of the duration of infection (preliminary results). After a challenge there was no decrease of the milk produccion in vaccined cows and the level of antibodies Anti-SAAC and Anti-J5 in milk and blood were higher. -
Understanding bovine mastitis as a dynamic enzootic.
Theron, L.; STARTVAC® Library 2013.
Epidemiological approach to mastitis at herd level. -
Case study, controlling clinical mastitis in a dairy herd using a multivalent vaccine.
May, T. W.; NMC 2013.
Increase of animals with SCC < 200.000, decrease of clinical mastitis rate, incidence of mastitis must be reduced by 10 cases per 100 cows per year in order to cover the costs of vaccination. -
Assessment of the use of STARTVAC® vaccine on a dairy farm affected by environmental mastitis.
Ribeiro, C.; STARTVAC® Library 2013.
Reduction of intramammary antibiotic treatment costs and decrease of BTSCC from 446.000 to 239.000. -
Case study, practical aproach for lowering the incidence of mastitis and the use of antibiotics on a dairy farm in Flanders.
Tacken, G.; NMC 2013.
Results were much less cases of acute severe mastitis, SCC reduction, culling rate reduction and reduction of mortalility, reduction in milk losses and treatment costs. -
The role of vaccination in Coliform mastitis control.
Bradley, A.; U. Ghent 2013.
Increase of milk production, decrease of mastitis severity (no culling for toxic mastitis). -
Case study, association between vaccination and dairy mastitis on a UK dairy farm.
Lindsay, C.; NMC 2013.
Reduction of SCC herd average, reduction of culling rate and clinical mastitis, reduction of duration of extended therapy , decrease of new infections and repeated cases. -
Case study, a milk quality programme in a UK dairy herd.
Drysdale, R.; NMC 2013.
Reduction of BTSCC, reduction of culling rate, reduction of clinical mastitis, increase of healthy animals < 200.000 cells/ml. -
STARTVAC® vaccination against bovine mastitis on dairy herd in central Ukraine.
Nikolayevich, G. V.; WBC 2012.
Reduction in clinical mastitis (6% to 2%), reduction in animal losses 3-5 to 1 per month, clearance of isolates of S. aureus, less use of antibiotics (reduction in 55-60%), increase in cure rate and BTSCC 257.000 to 163.000. -
Results of one year protocol with STARTVAC® mastitis vaccine, case study.
Sousa, J.; WBC 2012.
Reduction in BTSCC, S. aureus prevalence 19%to 3%, less systemic antibiotic treatments 24 to 10, less clinical mastitis cases 92 to 77. -
STARTCHECK, a new PCR diagnostic tool for bovine mastitis management.
Menezes, A.; WBC 2012.
Positive bulk milk samples for S. aureus, E. coli and coliforms are correlated with high BTSCC. -
Mastitis vaccination as a tool to improve milk quality, field study in a portuguese dairy farm.
Jimenez, L. M.; WBC 2012.
Redution of E. coli infections in 17%, reduction of clinical mastitis in 65% ,reduction of new infection rate 8,8% vs 11,8% and clearance of S. aureus isolates in vaccinated vs 3% in non vaccinated. -
Field study, use of STARTVAC® bovine mastitis vaccine on a swedish dairy farm.
Amroth, C.; WBC 2012.
Decrease BTSCC from 128.000 to 243.000, decrease in clinical and subclinical mastitis from 11,7% to 4,4%, decrease prevalence in CNS from 13,9% to 7,8%, E. coli slight decrease. -
STARTVAC® vaccination field trial in the northen region of Spain.
Ortega, R.; EBF 2011.
Less clinical mastitis 20% to 5%, reduction of mastitis causing pathogens prevalence E. coli 33,35 to 7,8%, S. aureus 11,7% to 2%, reduction of SCC 600.000 to 283.000 and increase of healthy cows 45% to 60%. -
Field experience with a bovine mastitis vaccine in the north-east of Spain.
Franquesa, O.; EBF 2011.
Decrease in SCC 330.000 to 305.000, increase of healthy cows from 55% to 64%, decrease of new infection rate from 26,4% to 19,8% and decrease of clinical mastitis rate 91,8% vs 67%. -
Coliform mastitis herd control program field experience.
Sesto, F.; EBF 2011.
BTSCC decrease from 246.000 to 210.000, more healthy cows, less chronic cows with SCC >1.000.000 cels/ml. -
Report on multifocal essays for the development of the STARTVAC® vaccine acording to a new protocol.
Schmitt. E., SNGTV 2011.
Reduction in mastitis rate 136 to 55% and in SCC 308.000 to 227.000. -
Report on multifocal essays for the development of the STARTVAC® vaccine acording to a new protocol.
Schmitt. E., STARTVAC Library 2011.
Reduction in mastitis rate 136 to 55% and in SCC 308.000 to 227.000. -
Efficacy of vaccination on mastitis epidemiology, field study.
Jimenez, L. M.; NMC 2010.
Reduction of new infection rate 8 vs 16 in cows and 6,2% vs 24,1% in primiparous, reduction of S. aureus isolates, increase of number of E. coli isolates, reduction in clincial mastitis 30% vs 43,2% in cows and 3,4% vs 13,3% in primiparous. -
Follow-up of farm use of a vaccine against staphylococcus and coliform mastitis (STARTVAC®, HIPRA).
Serieys, F.; SNGTV 2010.
Reduction of more than 25%somatic cell counts in multiparous cows, i.e. approximately 100,000 fewer cells/ml (P<0.05), and in nearly 30% fewer antibiotic treatments during lactation (P<0.05). -
Efficacy evaluation of a new vaccine against bovine mastitis, field trial results.
March, R.; NMC 2010.
Less clinical and subclinical mastitis, less severity in clinical mastitis (SCC, milk aspect, mamary gland aspect, mastitis treatments). -
Efficacy of an Escherichia coli J5 Mastitis vaccine in an experimental challenge trial.
Foix, A.; NMC 2009.
Challenge E. coli, reduction in the severity e.g. drop in milk and clinical signs, positive effect on bacterial clearance and SCC.